Sun Pharmaceutical Industries Limited — Important, 14-07-2025: General Updates

Sun Pharma has launched LEQSELVI™ (deuruxolitinib) in the U.S., a significant new treatment for adults with severe alopecia areata. This oral medication expands the company's dermatology portfolio, addressing a critical unmet patient need. Clinical trials showed rapid efficacy, with many patients achieving substantial hair regrowth. The launch positions Sun Pharma to capture market share in this under-served segment, potentially boosting future revenue. A patient support program is also in place to ensure accessibility.